15 May 2025 – London, UK (NTSE ‘DAVA’) Endava, a next-generation technology services partner whose AI-native approach combines cutting edge technology with deep industry expertise, has extended its collaboration with SOPHiA GENETICS, (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine. Together, they aim to accelerate innovation in precision medicine and genomic data analytics.
Since 2022, Endava has worked alongside SOPHiA GENETICS to co-develop enhancements that support more accurate, scalable and accessible data analysis across the SOPHiA DDM™ platform:
- Platform enhancements: Endava has supported improvements in the speed, accuracy, and scalability of SOPHiA DDM™ data analysis capabilities.
- Multimodal data integration: The collaboration has enabled integration of genomic, clinical, biological, and radiomic data, advancing how institutions generate and act on complex datasets.
- Refined visualisation capabilities: Enhanced tools have empowered healthcare professionals to gain precise insights, improving clinical decision-making and patient outcomes.
- Expanded global access: Increased accessibility means more hospitals, laboratories, and biopharma institutions are benefiting from next-gen data analytics, driving better care and more personalised treatments.
Now entering its fourth year, with an additional two-year engagement signed in 2025, the partnership continues to make strides in advancing healthcare:
Personalised cancer care: Endava is supporting the development of more personalised cancer care by helping SOPHiA GENETICS match treatments to patient-specific genomic profiles.
Further platform advancements: Evolution to SOPHiA DDM™ will enable multimodal data visualisation that guides clinical decision-making with enhanced accuracy.
AI-driven automation: Capitalising on the latest AI innovations to improve AI-powered automation, strengthen internal customer support processes and test case generation.
Scalability and flexibility: With integrated offshore capabilities, the platform can scale more effectively to meet the needs of healthcare professionals and institutions worldwide.
“We’re proud to continue partnering with SOPHiA GENETICS to support their vision for precision medicine,” said Isabela Buhai, Client Director, Healthcare and Life Sciences at Endava. “This collaboration reflects our shared commitment to improving access, insight and impact in healthcare.”
As healthcare institutions increasingly navigate a data-centric landscape, the challenge of integrating and analysing complex datasets grows. Endava and SOPHiA GENETICS remain focused on delivering accessible, scalable and secure solutions that enhances clinical decision-making to improve patient outcomes.
“The partnership with Endava has supported our mission to enable data-driven medicine at scale. The team’s deep expertise in cloud computing, AI-driven automation and advanced analytics has helped us strengthen the SOPHiA DDM™ platform for the healthcare community on a global scale,” said Abhimanyu Verma, Chief Technology Officer at SOPHiA GENETICS.
About Endava:
Endava is a leading provider of next-generation technology services, dedicated to enabling its customers to accelerate growth, tackle complex challenges and thrive in evolving markets. By combining innovative technologies and deep industry expertise with an AI-native approach, Endava consults and partners with customers to create solutions that drive transformation, augment intelligence and deliver lasting impact. From ideation to production, it supports customers with tailor-made solutions at every stage of their digital transformation, regardless of industry, region or scale.
Endava’s clients span payments, insurance, finance and banking, technology, media, telecommunications, healthcare and life sciences, mobility, retail and consumer goods and more. As of December 31 2024, 11,668 Endavans are helping clients break new ground across locations in Europe, the Americas, Asia Pacific and the Middle East.
About SOPHiA GENETICS:
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyses complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
Media contact: